Thank you to the team at On Deck for naming us among their Top Companies for the second year in a row! We're grateful for the recognition of our progress -- and we are just getting started! We've built a first-in-class drug discovery platform, moved into our new HQ, built a strong company culture across 2 continents, and are now in the final stages of prepping our multiple lead candidates for clinical trials. Stay tuned for more! https://lnkd.in/greUWTMG
Enveda Biosciences’ Post
More Relevant Posts
-
In an article spotlighting Cooley LLP's 2023 Life Sciences Group of the Year recognition, Law360 spoke with partners Marc Recht and Chad Shear, as they discussed how the firm's longstanding biotech industry leadership, collaborative workplace culture and breadth of practice play key roles in Cooley's accomplishments across the life sciences ecosystem. Subscribers can read more with the link below. #TeamCooley
Cooley Featured as Law360 Life Sciences Group of the Year – Law360
cooley.com
To view or add a comment, sign in
-
🟠 First Day Jitters or Ominous Signs? 🟠 It’s hard not to raise an eyebrow at Alumis Inc.’s rocky debut. A 17% nosedive on Day 1 isn’t exactly the ringing endorsement most IPOs aspire to, especially when you had to downsize your offering to drum up $250 million, padding that timid show with a private placement. Name a starker telltale sign that the market might be losing its appetite for clinical stage biopharma. There's a brutal reality beneath this spectacle: investor confidence isn’t bought in bulk. 🔸 Now, let’s face the facts: - **Shrinking IPO Size:** Going smaller with the public offering to garner even a whisper of interest? Sounds desperate, not promising. - **Launch Day Plummet:** A significant price drop on debut is a hard-to-miss red flag that might aim to reveal a stormy road ahead. 💼 **The Prediction Game:** I smell future turbulence for Alumis unless they showcase some groundbreaking clinical trial milestones—and fast. Shares are a heartbeat away from being branded toxic assets if clinical outcomes don't shift sentiment soon. Truly resilient organizations pivot quickly when faced with such stark market critiques. Alumis will need more than just scientific novelty; they’ll require visionary marketing and perhaps a revisit to burn rate strategies. Fingers crossed they don’t just become another cautionary tale for burgeoning biopharma IPOs. Sacrificial or Survivor? The next few months will tell. #Biopharma #IPO #MarketWatch #InvestmentInsights #PotentialInPeril https://lnkd.in/emdgfXDV
To view or add a comment, sign in
-
🏆 Calling all European Life Science Innovators! 🏆 Nominations are now open for the IPO / Listing of the Year award at the European Lifestars Awards! This is your opportunity to spotlight a team that has completed a significant, impactful, or transformational IPO on any international exchange, driving the future of life sciences with their groundbreaking achievements! This prestigious award acknowledges companies that have excelled in the following areas: 💰 Amount and type of funds raised 🏃♂️ Process / speed / allocation fulfillment of securing significant new funds 🤝 Level / reputation of new investors attracted 💼 Post-finance allocation / use of proceeds 🌟 Level of value creation / value realization from the raise To qualify you must: - Be a public company - Be a company with European headquarters - Have completed an IPO (primary listing, dual-listing, or uplisting) – NOT a secondary placement or follow-on Nominate a deserving company today and help us celebrate their dedication to innovation and growth in the European life sciences landscape! Cast your nomination here: https://lnkd.in/ezjTkn6f Watch the video of last year’s winner, NewAmsterdam Pharma Corporation, and get inspired by their success. Then, cast your nominations for this year’s standout performer! #LifestarsAwards #Innovation #LifeSciences #IPO
To view or add a comment, sign in
-
🚀 Elevate Your Brand with Endpoints News: A Featured Sponsored Post Opportunity! 🌐💼 For all fellow industry enthusiasts and business leaders amplify your brand's presence in the Biotech and Pharma space through a Featured Sponsored Post on Endpoints News. 🔍 Why Endpoints News? ✅ Unrivaled Industry Expertise: Navigate the intricate world of biotech and pharma with curated content from seasoned professionals. ✅ Global Reach: Reach a diverse and influential audience, ensuring your brand resonates across borders. ✅ Trendsetting Analysis: Stay ahead of the curve with trendsetting analyses, strategic intelligence, and exclusive reports. 🚀 Our Sponsored Post offers a prime opportunity to showcase your brand, product, or service alongside the latest industry trends. Position your company as a thought leader, reaching a vast and engaged community passionate about driving innovation. 📩 Reach out to [email protected] to do your next Featured Sponsored Post!! 📨 #Biotech #Pharma #EndpointsNews #SponsoredPost #Innovation #thoughtleadership #pharmaceutical #Healthcare #BrandVisibility #biopharma
Sponsored
https://endpts.com
To view or add a comment, sign in
-
Pharma D - Partner in Life Sciences. Biotech-Pharmaceutical Executive Global Commercial Leader. Multiple launch experience, Go-to Market Strategy , Ability to drive growth. lnnovative and Biosimilars
Discover the replay of our June 20th webinar, "The Roadmap to Success: From Founding your Biotech to a Successful Exit" featuring Marc de Garidel, Naveed Siddiqi, and myself Caroline BOULLIAT representing the views from Biotech, pharma and investors. 🔎Questions tackled during this webinar: 1. What are the key points to prepare successfully for an exit? 2. What are the takeaways from the exits of Cincor acquired by AstraZeneca and Corvidia acquired by Novo Nordisk? 3. What is the right time for an M&A? And for an IPO? 4. What are the key criteria for Pharma acquisition/Licensing? 5. What are the advantages and disadvantages of early vs later M&A? 6. What can biotech companies do better to enhance their attractiveness and readiness for M&A deals with pharma? 7. When do you integrate commercial strategy and market access into your development? 8. What potential pitfalls can occur during the deal process, and how can biotech companies anticipate and mitigate these risks? 9. How did you approach negotiations with potential buyers or partners during your M&A? 10. What is the advantage of partnering with pharma before an M&A and how to manage it? 11. What are the differences between dealing with medium-sized pharma companies versus large pharma firms? 12. What trends are emerging that could influence future exit (M&A) strategies? 13. How to manage a post-exit/Acquisition transition, as a company and as a CEO? 14. What advice for biotech CEOs who are considering an M&A soon? 15. Role of advisors, such as Genchrome, in playing a key role in facilitating deals between biotech and pharma companies? 🔗If you have any questions or would like a 30-minute call with us, please reach out to: [email protected] #exit #mergerandacquisition #assets #biotech#LOE
The Roadmap to Success: From Founding Your Biotech to a Successful Exit. Insights from Experts!
https://www.youtube.com/
To view or add a comment, sign in
-
Analyst at DigiU Pty Ltd | Driving Digital Transformation & Innovation | Passionate About Leveraging Technology for Business Success
🌟 Why Agile Falcon Strategic Group is Your Ultimate Wingman at the 17th DDSS Summit! 🌟 Ready to rock Munich on October 23-24? Join us at the 17th DDSS Summit, where we promise you'll find more than just pretzels and beer (although those are pretty great too)! 🔍 Perfect Business Matches: Think of it as speed dating, but with scientists and industry leaders. We've got the perfect lineup of folks with active needs and budgets for outsourcing your drug discovery services. Swipe right on success! 💸 ROI That'll Make Your Accountant Smile: Our pre-scheduled face-to-face meetings are like a GPS guiding you straight to your business goals. Who doesn't love a high return on investment? 🎯 Strategic Networking: Meet the movers and shakers of the drug discovery world. Build relationships that matter and skip the small talk. Your time is valuable, and so are the connections you'll make. 🤝 Not Just Business Cards: Leave with opportunities, partnerships, and maybe even a new best friend (or at least a LinkedIn connection). 🚀 Join Us in Munich on October 23-24! We guarantee your time will be well spent. Ready to elevate your Summit experience and drive your business forward? Message me for all the details on how Agile Falcon can make it happen. 🔗 https://lnkd.in/dSmySJWC #DDSSSummit #AgileFalcon #DrugDiscovery #Networking #Pharma #HealthcareInnovation #ROI #BusinessGoals #NoWastedTime
Home - 17th Drug Discovery Strategic Summit
ddsseu.agilefalconsg.com
To view or add a comment, sign in
-
Analyst at DigiU Pty Ltd | Driving Digital Transformation & Innovation | Passionate About Leveraging Technology for Business Success
🌟 Get Ready for the 17th DDSS Summit with Agile Falcon Strategic Group! 🌟 Hey science enthusiasts and industry leaders! The 17th DDSS Summit in Munich on October 23-24 is just around the corner, and Agile Falcon Strategic Group is excited to be a part of it! We know you have questions, and we're here to answer them all. 🤔 Curious About the Summit? - Want to know how our pre-scheduled face-to-face meetings work? - Interested in learning how you can maximize your ROI? - Wondering who you’ll meet and what opportunities await? 💬 Let's Chat! Drop your questions in the comments or send me a direct message! I’m here to provide all the details, share insights, and help you get the most out of this incredible event. 🚀 Join the Conversation! Don’t be shy—reach out and let’s make this Summit an unforgettable experience together. Whether you’re looking for networking tips or details on the event, I’ve got you covered! 🔗 https://lnkd.in/dSmySJWC #DDSSSummit #AgileFalcon #DrugDiscovery #Networking #Pharma #HealthcareInnovation #AskMeAnything
Home - 17th Drug Discovery Strategic Summit
ddsseu.agilefalconsg.com
To view or add a comment, sign in
-
Thanks to everyone that joined yesterday’s BPC x Cooley UK Biotech CEO event for a discussion on how to plan an exit strategy and navigate the preparations for cross over funding rounds and entering onto the public markets. We had three parts to the afternoons masterclass: ➡️An IPO bootcamp delivered by Courtney Tallman Thorne Partner at Cooley LLP the most active law firm representing biotechs listing in 2023 🔔🍾 ➡️ A panel discussion where we heard from the hands on experience of: Amit Shah from SR One Capital Management Dina Chaya from OrbiMed Elena Lovo, PhD from J.P. Morgan And Bobby Gaspar, CEO of Orchard Therapeutics ➡️ networking with a core group of biotech CEOs, investors, and industry experts 🧬🧪 My summary is that the experts believe we’re in for a much more upbeat year with as many as 36 biotech IPOs predicted for 2024 and that contenders are the companies that have compelling clinical data AND an investor base that can cover the book at least once over. For the others… it’s never too early to start planning! British Patient Capital Charlotte Davison Carmine Circelli Frances Stocks Allen Thomas Goodman
To view or add a comment, sign in
-
We're looking forward to Wednesday's Holiday CEO Summit and mingling with our members, sponsors and portfolio company CEOs like Jim Schulz of Scioto Biosciences, Inc. If you have not RSVP's, connect with Ben Pidgeon and he'll get you in. VisionTech Partners | VisionTech Angels #IndianaAngelInvesting #MidwestAngelInvesting
To view or add a comment, sign in
-
Yesterday, I shared details of the successful biopesticide companies / products selected to join Platform10's first field trial cohort. It was a highly competitive selection process. You can view the original story here: https://lnkd.in/grf7kH2v
To view or add a comment, sign in
20,027 followers